iSpecimen Inc. Reports Director Changes and Compensation Adjustments

Ticker: ISPC · Form: 8-K · Filed: Dec 30, 2024 · CIK: 1558569

Sentiment: neutral

Topics: management-change, compensation, governance

TL;DR

iSpecimen board shakeup and pay changes filed. Watch for new strategy.

AI Summary

On December 27, 2024, iSpecimen Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the departure of certain officers and directors, along with the election of new directors and adjustments to compensatory arrangements for key personnel. Specific details regarding the individuals involved and the financial implications of these changes are outlined within the report.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, potentially impacting investor confidence and stock performance.

Risk Assessment

Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future company direction and financial performance.

Key Numbers

Key Players & Entities

FAQ

Who are the specific directors or officers that have departed from iSpecimen Inc.?

The filing indicates the departure of certain officers and directors, but does not name them explicitly in the provided excerpt.

What are the key changes in the compensatory arrangements for iSpecimen Inc. officers?

The filing mentions adjustments to compensatory arrangements for certain officers, but the specific details of these changes are not provided in this excerpt.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on December 27, 2024.

What is the principal executive office address for iSpecimen Inc.?

The principal executive office address for iSpecimen Inc. is 8 Cabot Road, Suite 1800, Woburn, MA 01801.

What is the SIC code for iSpecimen Inc.?

The Standard Industrial Classification (SIC) code for iSpecimen Inc. is 8731, which falls under SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH.

Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2024-12-30 16:15:30

Key Financial Figures

Filing Documents

02(c). Appointment of Certain Officers

Item 5.02(c). Appointment of Certain Officers. On December 27, 2024, the Board of Directors (the "Board") of iSpecimen Inc. (the "Company"), by written consent, appointed Mr. Robert Bradley Lim, the Company's Chief Executive Officer, to the additional roles of Treasurer and Secretary of the Company in accordance with the Company's Second Amended and Restated Bylaws. There were no changes to Mr. Lim's compensation or other terms of employment in connection with this appointment.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 30, 2024 iSPECIMEN INC. By: /s/ Robert Bradley Lim Name: Robert Bradley Lim Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing